BioSpace News Archive

Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 90,400 shares of its common stock to one employee outside Fusion’s 2020 Stock Option and Incentive Plan.

Antares Pharma, Inc. today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Ladenburg Thalmann Annual Healthcare Conference.

Vericel Corporation today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Ladenburg Thalmann Healthcare Conference.

Aadi Bioscience, Inc. today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July 13, 2021.

Health Logic Interactive Inc. (“Health Logic” or the “Company”) (TSXV: CHIP.H)(OTCPK: CHYPF), is pleased to announce its first update to our digital diagnostic device MATLOC 1.

Collaboration is poised to deliver a range of ready-to-use bioprocess impurity reagent sets optimized for use with the Gyrolab platform

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company installed its technology in a leading New York City hospital.

- Phase 3 Mino-Lok® trial proceeding as planned following recommendation by independent Data Monitoring Committee (DMC), highlighting important safety and efficacy signals - - Mino-Lok® New Drug Application (NDA) submission planned for 2022 following anticipated completion of Phase 3 trial by the end of 2021 or early 2022 -

The Cancer and Blood Specialty Clinic (CBSC) and Deep Lens announced today that they have entered into a strategic partnership to integrate artificial intelligence (AI)-based clinical trial matching solution, VIPER™, into the Southern California-based practice. VIPER uses proprietary, cloud-based technology to facilitate, triage and accelerate the clinical trial recruitment process.

Zebra Medical Vision, the leading medical imaging analytics company, announces an industry-first, landmark approval of a Category III Current Procedural Terminology (CPT) code application for utilizing AI for VCF detection as an incidental finding in chest CT, by the American Medical Association (AMA)